Milestone Pharmaceuticals appoints Dr. David Bharucha as CMO; grants 330,000 option inducement award

Milestone Pharmaceuticals Inc.

Appointed Dr. David Bharucha as CMO effective Feb 15, 2022.
Granted inducement option to purchase 330,000 common shares vesting over 4 years.
Base salary $445,000 and target annual bonus of 40% of base salary.
Prior CMO Francis Plat becomes Chief Scientific Officer; advisory role after RAPID trial.

item 3.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David Bharucha

Chief Medical Officer

MIST · Milestone Pharmaceuticals Inc.

Effective: 2022-02-15
Filed: February 16, 2022, 6:59 PM ET

Appointment of Chief Medical Officer On February 16, 2022, the Company announced the appointment of Dr. Bharucha as the Company’s Chief Medical Officer, effective February 15, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Bharucha was appointed as Chief Medical Officer at Milestone Pharmaceuticals Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Appointment of Chief Medical Officer On February 16, 2022, the Company announced the appointment of Dr. Bharucha as the Company’s Chief Medical Officer, effective February 15, 2022.

View on SEC.gov

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-024083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.